Public-private partnership will support first and only trial to reduce hippocampal overactivity during aMCI, the pre-dementia stage of Alzheimer’s disease BALTIMORE, MD, September 15, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today…
First and only clinical trial to reduce hippocampal overactivity during aMCI, the pre-dementia stage of Alzheimer’s disease Restored brain function to pre-disease levels and significantly improved memory BALTIMORE, MD March 11, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing…
Phase 3-ready AGB101 designed to address aMCI, the pre-dementia stage of Alzheimer’s disease BALTIMORE, MD January 28, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia stage…
BALTIMORE, MD January 7, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia phase of Alzheimer’s disease, and other neurological and psychiatric diseases, today announced that the…
BALTIMORE, MARYLAND—AgeneBio, a pharmaceutical company developing innovative therapeutics that prevent neurodegeneration and preserve and restore brain function, today announced that the Company’s founder and chief scientific officer Michela Gallagher, PhD, has received the Society for Neuroscience’s Mika Salpeter Lifetime Achievement…
BALTIMORE, MARYLAND—AgeneBio, Inc., a clinical-stage pharmaceutical company developing medicines to restore and preserve patients’ cognitive function for a range of debilitating neurodegenerative diseases, today announced the appointment of Patrick LePore as chairman of the board and Jerry McLaughlin as president…
